{"id":"W2922010177","doi":"10.1200/jco.2019.37.7_suppl.tps346","title":"Personalized use of metronomic cyclophosphamide for DNA repair deficient castration-resistant prostate cancer: A phase II trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Olaparib; Medicine; Prostate cancer; PARP inhibitor; Veliparib; Oncology; Internal medicine; Cyclophosphamide; Clinical endpoint; Cancer; Cancer research; Clinical trial; Chemotherapy; Poly ADP ribose polymerase; DNA; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007739891,0.00115903,0.001094452,0.0004846899,0.0002909281,0.0008965886,0.0007664834,0.001245907,0.006382851],"category_scores_gemma":[0.0003793479,0.0004151974,0.001129421,0.0004502184,0.0006280793,0.0007860587,0.0003266437,0.002385209,0.0007237059],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006391534,"about_ca_system_score_gemma":0.0009968816,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006679549,"about_ca_topic_score_gemma":0.001870575,"domain_scores_codex":[0.9997771,0.00008586505,0.000009605728,0.00003686106,0.0000258228,0.00006462856],"domain_scores_gemma":[0.9997486,0.00003095311,0.00006464249,0.00002547199,0.00001085382,0.0001195367],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.645884,0.05358147,0.004636483,0.001957234,0.001871264,0.0002942293,0.000247939,0.004583533,0.03477752,0.0008443913,0.00545554,0.2458665],"study_design_scores_gemma":[0.6560198,0.3246631,0.01009815,0.00008755037,0.000530654,0.0003416056,0.00005279175,0.00154874,0.002770747,0.0003900566,0.003456865,0.00003992511],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9855005,0.004392287,0.0009076435,0.0009286689,0.0001864769,0.003415774,0.001900244,0.0002278181,0.002540571],"genre_scores_gemma":[0.9867032,0.002774981,0.001722267,0.001405267,0.0001742853,0.00251266,0.001895943,0.00002838243,0.002782946],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006382851,"threshold_uncertainty_score":0.02135277,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1884027653588639,"score_gpt":0.5044325240745496,"score_spread":0.3160297587156857,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}